文献速递乳腺癌放疗

新冠疫情对日本乳腺癌大分割放射治疗使用的影响:全国性研究

Impact of the COVID-19 Pandemic on Hypofractionated Radiation Therapy Use for Breast Cancer in Japan: A Nationwide Study.
PubMed 文献 · Adv Radiat Oncol · 2024-06-25

该研究利用日本全国健康保险索赔数据库,采用中断时间序列分析评估新冠疫情对乳腺癌大分割放疗使用的影响。疫情期间大分割放疗在2020年4月显著增加(1312疗程;95%CI 801-1823),但2020年10月下降(-601;95%CI -1111至-92),增加未持续。尽管大分割放疗逐渐替代常规放疗,常规放疗仍占主导,作者建议在日本鼓励使用大分割放疗。

要点

  • 疫情前大分割放疗逐渐增加而常规放疗逐渐减少,但常规放疗始终多于大分割放疗。
  • 疫情暴发后大分割放疗在2020年4月显著增加(1312疗程;95%CI 801-1823)。
  • 2020年10月大分割放疗下降(-601;95%CI -1111至-92),增加未持续。

核心结论

  • 尽管常规放疗逐渐被大分割放疗替代,但常规放疗仍占主导地位。
  • 大分割放疗在疫情早期短暂增加,但未像其他国家那样持续。
  • 考虑到大分割放疗对乳腺癌的获益,作者认为应在日本鼓励其使用。

研究设计与样本

  • 使用日本全国健康保险索赔和特定健康检查数据库的样本数据集,统计每月大分割和常规放疗的疗程数。
  • 采用中断时间序列分析估计大分割和常规放疗数量的变化。

主要发现

  • 疫情前大分割放疗疗程数逐渐增加,而常规放疗疗程数逐渐减少。
  • 整个观察期间常规放疗疗程数始终多于大分割放疗。
  • 疫情暴发后,大分割放疗在2020年4月显著增加(1312疗程;95%CI 801-1823)。
  • 大分割放疗在2020年10月下降(-601;95%CI -1111至-92)。
  • 按年龄和医疗机构床位数分层的亚组分析显示相似趋势。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为,考虑到大分割放疗对乳腺癌的获益,应在日本鼓励其使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Hypofractionated radiation therapy (RT) was recommended for several cancer sites to reduce outpatient visits during the COVID-19 pandemic. This study aimed to identify the impact of the pandemic on hypofractionated RT for breast cancer in Japan. METHODS AND MATERIALS: The monthly number of courses for hypofractionated and conventional RTs was counted using sample data sets from the National Database of Health Insurance Claims and Specific Health Checkups of Japan, a nationwide database accumulating insurance claims data comprehensively. Changes in the number of hypofractionated and conventional RTs were estimated using an interrupted time-series analysis. RESULTS: The number of hypofractionated RT courses gradually increased before the pandemic in contrast to that of conventional RT courses, which gradually decreased. However, conventional RT remained outnumbered by hypofractionated RT throughout the observation period. After the outbreak of the pandemic, the use of hypofractionated RT significantly increased in April 2020 (1312 courses; 95% CI, 801-1823) but decreased in October 2020 (-601; 95% CI, -1111 to -92). Subgroup analysis by age and the number of beds in medical institutions revealed similar trends. CONCLUSIONS: Although conventional RT for breast cancer has been gradually replaced by hypofractionated RT, it remains predominant. The use of hypofractionated RT increased briefly early in the COVID-19 pandemic; however, this increase was not sustained, unlike in other countries. Considering the benefits of hypofractionated RT for breast cancer, its use should be encouraged in Japan.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Fujita M, Nagashima K, Uno T, et al. Impact of the COVID-19 Pandemic on Hypofractionated Radiation Therapy Use for Breast Cancer in Japan: A Nationwide Study. Adv Radiat Oncol. 2024. PMID: 39104876. doi:10.1016/j.adro.2024.101555

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。